Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30732442 | 1.00 | APLNR (0.44) | APLNRDGAT1KDM1AKDM1BALOX5AP | |
| SCHEMBL248835 | 0.83 | DGAT1 (0.38) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL29604357 | 0.83 | DGAT1 (0.38) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL16104803 | 0.82 | APLNR (0.49) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL3872105 | 0.81 | APLNR (0.44) | APLNRDGAT1KDM1AKDM1BALOX5AP | |
| SCHEMBL3988011 | 0.80 | APLNR (0.47) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL10719 | 0.80 | APLNR (0.47) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL30169618 | 0.79 | APLNR (0.50) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL2550576 | 0.79 | APLNR (0.50) | APLNRDGAT1KDM1AKDM1BNPC1 | |
| SCHEMBL15861423 | 0.77 | APLNR (0.49) | APLNRDGAT1KDM1AKDM1BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025122545-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2025-06-05 | — | — | US | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025043151-A2 | BICYCLIC DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20250066363-A1 | Bicyclic DGK Inhibitors | INCYTE CORPORATION | 2025-02-27 | — | — | US | disclosed |
| EP-4512801-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | Kissei Pharmaceutical Co., Ltd. (JP) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066363-A1 | Bicyclic DGK Inhibitors | DGKA, DGKG, DGKK | APLNR 2961/4885DGAT1 11/4885KDM1A 3332/4885 |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | APLNR 3366/4885DGAT1 14/4885KDM1A 3553/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | APLNR 1196/4885DGAT1 1088/4885KDM1A 2698/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | APLNR 4123/4885DGAT1 486/4885KDM1A 407/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | APLNR 608/4885DGAT1 3383/4885KDM1A 4486/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | APLNR 4123/4885DGAT1 486/4885KDM1A 407/4885 |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | APLNR 2204/4885DGAT1 2748/4885KDM1A 3500/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | APLNR 1518/4885DGAT1 2267/4885KDM1A 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.